Tafamidis

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Transthyretin (TTR) Amyloid Cardiomyopathy

Conditions

Transthyretin (TTR) Amyloid Cardiomyopathy

Trial Timeline

Jun 13, 2016 → Nov 2, 2023

NCT ID

NCT02791230

About Tafamidis

Tafamidis is a phase 3 stage product being developed by Pfizer for Transthyretin (TTR) Amyloid Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02791230. Target conditions include Transthyretin (TTR) Amyloid Cardiomyopathy.

What happened to similar drugs?

3 of 18 similar drugs in Transthyretin (TTR) Amyloid Cardiomyopathy were approved

Approved (3) Terminated (0) Active (15)

🔄Eplontersen + PlaceboAstraZenecaPhase 3

🔄EplontersenAstraZenecaPhase 3

🔄Eplontersen + PlaceboAstraZenecaPhase 3

🔄NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3

✅tafamidis megluminePfizerApproved

🔄tafamidisPfizerPhase 3

✅TafamidisPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06393465	Pre-clinical	Active	Jun 15, 2024	Feb 20, 2026	Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
NCT06086353	Pre-clinical	Completed	Mar 25, 2024	Jun 6, 2025	Transthyretin Amyloid Cardiomyopathy
NCT05139680	Pre-clinical	Completed	Mar 8, 2023	May 19, 2023	Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
NCT05560555	Pre-clinical	Completed	Oct 24, 2022	Nov 15, 2022	Hereditary Transthyretin Amyloidosis (ATTRv)
NCT04814186	Approved	Completed	Jul 22, 2021	Oct 16, 2023	Transthyretin Amyloid Cardiomyopathy
NCT03662191	Phase 1	Completed	Sep 28, 2018	Jan 10, 2019	Healthy Volunteers
NCT03280173	Phase 1	Completed	Sep 29, 2017	Feb 23, 2018	Healthy
NCT03266705	Phase 1	Completed	Sep 20, 2017	Mar 1, 2018	Healthy
NCT02791230	Phase 3	Completed	Jun 13, 2016	Nov 2, 2023	Transthyretin (TTR) Amyloid Cardiomyopathy
NCT02746926	Phase 1	Completed	Apr 29, 2016	Jul 15, 2016	Healthy
NCT02697864	Phase 1	Completed	Apr 1, 2016	Jun 1, 2016	Healthy
NCT01435655	Phase 3	Completed	Nov 1, 2011	Feb 1, 2014	Transthyretin Familial Amyloid Polyneuropathy
NCT00935012	Phase 3	Completed	Sep 30, 2009	Nov 20, 2019	ATTR-CM
NCT00925002	Phase 3	Completed	Aug 5, 2009	Jul 8, 2020	ATTR-PN

Competing Products

20 competing products in Transthyretin (TTR) Amyloid Cardiomyopathy

See all competitors

Product	Company	Stage	Hype Score
Eplontersen Solution for Injection	AstraZeneca	Phase 1	29
Eplontersen + Placebo	AstraZeneca	Phase 3	44
Treatment of transthyretin (ATTR) amyloidosis in observational study setting	AstraZeneca	Pre-clinical	33
Eplontersen	AstraZeneca	Phase 3	47
Eplontersen + Placebo	AstraZeneca	Phase 3	44
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 3	47
NNC6019-0001	Novo Nordisk	Phase 2	39
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 2	35
Coramitug	Novo Nordisk	Phase 1	36
Tafamidis	Pfizer	Pre-clinical	26
Tafamidis	Pfizer	Pre-clinical	30
tafamidis meglumine	Pfizer	Approved	43
Fx-1006A	Pfizer	Phase 2	35
Tafamidis 61 milligrams	Pfizer	Pre-clinical	26
Treatment for TTR amyloidosis + Treatment for TTR amyloidosis	Pfizer	Pre-clinical	26
Vyndaqel	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Phase 3	40
Tafamidis	Pfizer	Approved	43
Tafamidis	Pfizer	Pre-clinical	26
Vyndamax (tafamidis 61mg)	Pfizer	Pre-clinical	30